Incorporating bortezomib into the treatment of lung cancer
Incorporating bortezomib into the treatment of lung cancer
复制标题
DOI：
10.1158/1078-0432.ccr-07-0334
复制
发表时间：
2007-08-01
影响因子：
11.5
通讯作者：
Gandara, David R.
中科院分区：
文献类型：
--
作者：
Davies, Angela M.;Lara, Primo N., Jr.;Gandara, David R.
硼替佐米是一种小分子蛋白酶体抑制剂，无论是单独使用还是与肺癌常用药物联合使用，都对肺癌有活性。硼替佐米有利地调节a光相关蛋白表达的能力，以及其作为单一药物的中等毒性，为其与细胞毒性药物联合治疗肺癌提供了基础。在非小细胞肺癌中，硼替佐米作为单一药物的活性有限，但与化疗联合使用显示出令人鼓舞的活性，而不会显著增加毒性。硼替佐米作为单一药物在小细胞肺癌中显示出最小的活性。虽然硼替佐米在肺癌中的作用尚不确定，但当与其他治疗药物联合使用时，它可能具有最大的临床益处。正在进行的研究主要集中在优化硼替佐米与化疗的计划，研究其与靶向药物和放疗的联合，并检查其在特定亚组，细支气管肺泡癌中的疗效。
Bortezomib, a small-molecule proteasome inhibitor, has activity in lung cancer both as a single agent and in combination with agents commonly used in lung cancer. The ability of bortezomib to favorably modulate the expression of a p optosis-associated proteins, along with its moderate toxicity as a single agent, provides the basis for its combination with cytotoxic agents in the treatment of lung cancer. In non - small cell lung cancer, bortezomib as a single agent has limited activity but in combination with chemotherapy has shown encouraging activity without significantly adding to toxicity. Bortezomib as a single agent has shown minimal activity in small cell lung cancer. Although the role of bortezomib in lung cancer is uncertain, it is likely to have its greatest clinical benefit when given in combination with other therapeutics. Ongoing studies are focused on optimizing the scheduling of bortezomib with chemotherapy, investigating its combination with targeted agents and radiation, and examining its efficacy in a specific subgroup, bronchioloalveolar carcinoma.